Selective Grb2 SH2 inhibitors as anti-Ras therapy

International Journal of Cancer

Volumn 83, Issue 2, 1999, Pages 235-241

  Gay, Brigitte ^a   Suarez, Stéphanie ^a   Caravatti, Giorgio ^a   Furet, Pascal ^a   Meyer, Thomas ^a   Schoepfer, Joseph ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CGP 78850; CGP 85793; EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

3T3 CELLS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL CYCLE PROTEINS; CELL LINE, TRANSFORMED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DRUG DESIGN; GRB2 ADAPTOR PROTEIN; HUMANS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEINS; RAS PROTEINS; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; SRC HOMOLOGY DOMAINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0032880670     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19991008)83:2<235::AID-IJC15>3.0.CO;2-B     Document Type: Article

References (21)

1. CANTLEY, L.C. and SONGYANG, Z., Specificity in recognition of phosphopeptides by src-homology 2 domains. J. Cell Sci., (Suppl. 18), 121-126 (1994).
2. 1 arrest with inhibition of CDK2 and CDK4 in human breast carcinoma cells. Cancer Res., 56, 2973-2978 (1996).
3. CATZAVELOS, C. and 12 others. Decreased levels of the cell-cycle inhibitor p27kip1 protein: Prognostic implications in primary breast cancer. Nature (Med)., 3, 227-230 (1997).
4. DATI, C., MURACA, R., TAZARTES, O., ANTONIOTTI, S., PERROTEAU, I., GIAI, M., CORTESE, P., SISMONDI, P., SAGLIO, G. and DE BORTOLI, M., C-erbB-2 and Ras expression levels in breast cancer are correlated and show a cooperative association with unfavorable clinical outcome. Int. J. Cancer, 65, 45-50 (1991).
5. FURET, P., GAY, B., CARAVATTI, G., GARCIA-ECHEVERRIA, C., RAHUEL, J., SCHOEPFER, J. and FRETZ, H., Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain. J. med. Chem., 41, 3442-3449 (1998).
6. GARCIA-ECHEVERRIA, C., STAMM, C., ROMAN, W., ARZ, D. and GAY, B., Biotinylated phosphotyrosine-containing peptides: a valuable tool for studies on phosphopeptide interactions with SH2 and PTB domains. Lett. Pept. Sci., 4, 49-53 (1997).
7. GULLICK, W.J., Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Brit. med. Bull., 47, 87-98 (1991).
8. HARPER, J. W., ADAMI, G.R., WEI, N., KEYOMARSI, K. and ELLEDGE, S.J., The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805-816 (1993).
9. HUNTER, T. and PINES, J., Cyclins and cancer. Cyclin D and CDK inhibitors come of age. Cell, 79, 573-582 (1994).
10. JANES, P.W., LACKMAN, M., CHURCH, W.B., SANDERSON, G.M., SUTHERLAND, R.L. and DALY, R., Structural determinants of the interaction between erbB2 receptor and the Src homology 2 domain of Grb7. J. biol. Chem., 272, 8490-8497 (1997).
11. JHAPPAN, C., STAHLE, C., HARKINS, R.N., FAUSTO, N., SMITH, G.H. and MERLINO, G.T., TGFα overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell, 61, 1137-1146 (1990).
12. LOWE, P.N. and SKINNER, R., Regulation of Ras signal transduction in normal and transformed cells. Cell Signalling, 6, 109-123 (1994).
13. MCGUICAN, C., DEVINE, K.G., O'CONNOR, T.J., GALPIN, S.A., JEFFRIES, D.J. and KINCHINGTON, D., Synthesis and evaluation of some novel phosphoramidate derivatives of 3′-azido-3′-deoxythymidine (AZT) as anti-HIV compounds. Antiviral Chem. Chemother., 1, 107-113 (1990).
14. PENG, D., FAN, Z., LU, Y., DEBLASIO, T., SCHER, H. and MENDELSOHN, J., Anti EGFR monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res., 56, 3666-3669 (1996).
15. PRENDERGAST, G. C. and GIBBS, J.B., Ras regulatory interactions: novel targets for anti-cancer intervention? BioEssays, 16, 187-191 (1994).
16. RAHUEL, J., GAY, B., ERDMANN, D., STRAUSS, A., GARCIA-ECHEVERRIA, C., FURET, P., CARAVATTI, G., FRETZ, H., SCHOEPFER, J. and GRUETTER, M.G., Structural basis for specificty of Grb2-SH2 revealed by a novel ligand binding mode.. Nature (Struct. Biol.), 3, 586-589 (1996).
17. SCHLESSINGER, J., SH2/SH3 signaling proteins. Curr. Opin. Genet. Dev., 4, 25-30 (1994).
18. TAKENAWA, T., MIKI, H. AND MATUOKA, K. Signaling through Grb2/Ash-control of the Ras pathway and cytoskeleton. In: R.W. Compans, M. Cooper, J.H. Hogle, H. Koprowski, M. Oldstone, M. Potter and P.K. Vogt (eds.), Current topics in microbiology and immunology, vol. 228, pp. 325-342, Springer-Verlag, Berlin (1998).
19. VERBEEK, B.S., ADRIAANSEN-SLOT, S.S., RUKSEN, G. and VROOM, T.M., Grb2 overexpression in nuclei and cytoplasm of human breast cells: a histochemical and biochemical study of normal and neoplastic mammary tissue specimens. J. Pathol., 183, 195-203 (1997).
20. WOODS, D., PARRY, D., CHERWINSKI, H., BOSCH, E., LEES, E., and MCMAHON, M., Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol., 17, 5598-5611 (1997).
21. WRIGHT, C., ANGUS, B., NICHOLSON, S., SAINSBURY, J.R.C., CAIRNS, J., GULLICK, W.J., KELLY, P., HARRIS, A.L. and HORNE, C.H.W., Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res., 49(8), 2087-2090 (1989).